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Lymphoma affects many young women of childbearing age. The American Society of Clinical 
Oncology recommends early discussion of the reproductive risks of treatment, and referral to 
fertility preservation (FP) specialists when appropriate (Loren, et al 2013). Women referred for 
FP undergo a several-step process including ovarian stimulation, oocyte retrieval, and oocyte or 
embryo storage (De Vos et al 2014). Barriers to FP include poor access to reproductive 
specialists and concerns for treatment delay (Quinn, et al 2015, Quinn, et al 2009). The real-
world treatment delay and outcomes among female lymphoma patients attempting FP with 
modern techniques have not been reported previously.  
     At our institution, practitioners are required to address fertility in all newly diagnosed cancer 
patients through the use of automated prompts in the electronic medical record. We have a 
dedicated in-house fertility preservation patient navigator (FPPN) to educate patients and 
expedite referrals to the reproductive specialists. We performed a retrospective chart review of 
lymphoma patients that contacted any fertility specialist prior to treatment at Northwestern 
University from 1 May 2006 until 31 August 2015. Patients who underwent FP were compared 
to women that contacted a FPPN but did not undergo preservation.  The Northwestern 
University institutional review board approved the use of the clinical database for this project.  
    Our primary objective was to assess differences in time to treatment (TTT) associated with FP. 
In newly diagnosed patients, TTT was defined as the time from the initial haematology 
consultation until the initiation of therapy. In patients with relapsed disease, TTT was defined as 
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secondary objective was to assess progression-free survival (PFS), which was defined as time 
from date of treatment until progression or death.  The Wilcoxon rank sum test was used to 
compare age, TTT and follow-up time between groups.  Fisher’s exact test was used to compare 
stage, planned treatment setting, and Eastern Cooperative Oncology Group performance score 
(ECOG PS).  Kaplan-Meier curves with the log rank test were used to compare PFS between the 
two groups, using a two-tailed significance level of 0.05.  
A total of 128 patients were identified from a fertility patient log, including 40 who 
underwent FP. Thirty-three of 40 patients undergoing FP and 50 of 93 patients who chose not to 
undergo FP were available for analysis. Reasons for exclusion included patients seen by 
reproductive endocrinology only and no haematologist consulted at Northwestern, lack of 
chemotherapy treatment records, or no treatment received following fertility contact. Pertinent 
baseline characteristics are outlined in Table I. Comparing the two groups, there was a 
significant difference in age (p=0.01), but not in stage (p=0.05), planned treatment setting 
(p=0.99) or ECOG PS (p=0.99). Median follow-up was 39.3 (1.5 – 103.4) months, and did not 
differ between controls and those undergoing FP (p=0.16).  
     Median TTT among FP patients was 28 days overall (range: 18-76) versus 15.5 days (range: 0-
74) for controls (p< 0.001; Figure 1A). Factors other than FP led to treatment delays prior to and 
after FP.   The median time to first contact with a fertility specialist was 0 days (range -15 to 
+11) from haematology consultation, with several patients having contact prior to their 
haematology visit. The median time from oocyte retrieval until treatment initiation was 5 days 
(range 0-21). Seven patients had greater than 8 days from oocyte collection to treatment. The 
reasons were variable: 3 had delays in diagnostic work-up; 1 deferred for a trip out of town; 2 
were treated subsequently at an outside institution; and 1 had follicular lymphoma with no 
urgency to treat. The median number of days to complete stimulation protocol was 11 (range: 
5-14). A median of 14 oocytes (range: 0-37) were retrieved per patient. In 2 women, no oocytes 
could be successfully retrieved. Five women achieved pregnancy following FP compared to 6 
controls. Of these, 3 were spontaneous and 2 required reproductive assistance, one from frozen 
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were successful and 1 was unsuccessful. Ovarian stimulation did not result in any known 
complications.  
     In total, 15 patients relapsed after contacting a fertility specialist, including 7 patients in the 
control group and 8 in the FP arm. Patients who subsequently relapsed in both arms had high-
risk features prior to fertility. There was no difference in 1-year and 5-year PFS between FP 
patients compared to controls (FP: 1-year PFS=81.6%, 5-year PFS = 71.4%; Controls: 1-year PFS 
=93.8%, 5-year PFS= 83.7%, p=0.17; Figure 1B).  
     Our study has some limitations, including those associated with a retrospective analysis.  
Only patients who contacted a fertility specialist were included and therefore our analysis is 
subject to selection bias.  Our population was heterogeneous with a wide range of lymphoma 
subtypes, stages and treatments received. Additionally, the relatively small number of patients 
available for analysis limited our ability to match patients based on age, disease or prognosis, 
and thus there were some baseline differences between groups.  However, our uniform method 
of referral is a major strength of our study. To our knowledge, our institution is one of the few 
major universities with a FPPN to centralize the collection of data on women undergoing FP, and 
provides a bridge between the fields of reproductive endocrinology and malignant 
haematology. Overall, this analysis provides important information regarding the expected 
delays and outcomes associated with FP. Our study demonstrates that if referral is prompt, FP 
contributes minimal delay to treatment and is not associated with adverse outcomes.  
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Table I. Patient Characteristics 
 










26 (20-35) 29 (17-45) 
       
 33 (100) 21 (67) 12  (33) 50 (100) 31  (62) 19  (38) 
   
       Frontline 25 (76) 14 (67) 11 (92) 37 (74) 24 (77) 13 (68) 
       R/R 8 (24) 7   (33) 1   (8) 13 (26) 7   (23) 6   (32) 
   
       ABVD 12 (36) 12 (57) --- 23 (46) 23 (74) --- 
       R-CHOP-like † 8   (24) --- 8  (64) 6   (12) --- 6  (32) 
       escBEACOPP 2 (6) 2   (10) --- 1   (2) 1   (3) --- 
       DA-EPOCH-R 2 (6) --- 2  (18) 4   (8) --- 4  (21) 
       R-Hyper-CVAD 1 (3) --- 1  (9) 4   (8) --- 4  (21) 
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      Other
‡ 1   (3)  1 (9) 2   (4)  2  (11) 
§   
       I/II 28 (85) 17 (81) 11 (92) 32 (64) 23 (74) 9  (47) 
       III/IV 5 (15) 4   (19) 1   (8) 17 (34) 8   (26) 9  (47) 
 9 (27) 6   (29) 3  (25) 10 (20) 4   (13) 6  (32) 
¥   
       0 24 (73) 17 (81) 7  (58) 38 (76) 22 (71) 16  (84) 
      ≥ 1 5 (12) 2   (10) 3  (25) 9   (18) 6   (19) 3    (16) 
 9 (27) 4   (19) 5  (42) 17 (34) 7   (23) 10 (53) 
 9 (27) 9   (43)  11 (22) 11 (35)  
 10 (30) 8   (38) 2  (17) 19 (38) 13 (42) 6  (32) 
 
HL: Hodgkin lymphoma; NHL: non-hodgkin lymphoma; R/R: relapsed/refractory; ABVD: 
Adriamycin, bleomycin, vinblastine, dacarbazine; R-CHOP: rituximab, cyclophosphamide, 
Adriamycin, vincristine, prednisone; escBEACOPP: escalated bleomycin, etoposide, 
Adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; DA-EPOCH-R: dose 
adjusted etoposide prednisone, vincristine, cycophosphamide, Adriamycin, rituximab; R-
HyperCVAD: Course A- cyclophosphamide, vincristine, Adriamycin, dexamethasone, 
cytarabine, mesna, methotrexate; Course B- methotrexate, leucovorin, cytarabine; HDCT + 
SCT: high dose chemotherapy plus stem cell transplant; ECOG PS: Eastern Cooperative 
Oncology Group performance status; LDH: lactate dehydrogenase; ULN: upper limit of 
normal; ESR: erythrocyte sedimentation rate. 
 
* % Percent of specified histology 
† R-CHOP, BR (bendamustine rituximab), R-CVP (rituximab, cyclophosphamide, vincristine, 
prednisone) 
‡ Involved field radiotherapy, radio-immunotherapy, romidepsin 
§ One patient with NHL seen at relapse, initial staging information not available. 
¥ ECOG PS missing for 3 HL patients in control group, and 2 HL and 2 NHL in the fertility 
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Figure 1 
(A) Time to treatment among patients undergoing fertility preservation versus controls. 
Patients undergoing fertility preservation had longer time to treatment (p < 0.001). The 
median times to treatment were 28 and 15.5 days in patients undergoing and not 
undergoing fertility preservation respectively. (B) There was no difference in 5-year 
progression-free survival between patients undergoing or not undergoing fertility 
preservation (p=0.11). 
CTL: control; FP: fertility preservation.  
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